About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Adult Spinal Muscular Atrophy (SMA) China Registry | Clinical Trials | Clareo Health

Back to clinical trial search

Active Not RecruitingNCT05618379

Adult Spinal Muscular Atrophy (SMA) China Registry

The primary objective of the study is to describe the natural history and utilization of disease modifying therapy (DMT) among adult Chinese participants with SMA linked to chromosome 5q (5q-SMA).

Lead sponsor: Biogen•12 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Sponsors

Lead Sponsor

Biogen

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Genetically confirmed 5q-SMA.

Exclusion Criteria

•Other types of SMA (non 5q-SMA).

Related studies

RECRUITINGPhase 2

A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy

NCT05808764 · Muscular Atrophy, Spinal

RECRUITINGPhase 4

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy

NCT05861986 · Muscular Atrophy, Spinal

Natural History of SMA

NCT05755451 · Muscular Atrophy, Spinal

Active Not RecruitingPhase 1

A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec

NCT05575011 · Healthy Volunteer, Muscular Atrophy, Spinal

COMPLETEDPhase 2

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants

NCT02908685 · Muscular Atrophy, Spinal

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 11, 2025Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

Phase—

Enrollment200

Start dateJan 2023

Last updatedJul 11, 2025

Condition

Muscular Atrophy, Spinal

Locations shown

Peking Union Medical College Hospital

Beijing, Beijing Municipality

The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian

The First Affiliated Hospital, Sun Yat-sen University

Guangzhou, Guangdong

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 11, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions